SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: I_Banker who wrote (325)1/5/2005 3:41:42 PM
From: idahoranch1  Read Replies (1) of 371
 
It is estimated that 1.5 million people suffer from lupus in the US, and 20% of those are chronic, so at least 300,000 people that might need to be on a maintenance treatment. It is a pretty big market. We should get an update on Sjogrens sometime in the first half of this year, that market isn't quite as big, but if the data is anywhere near as compelling as the lupus data (only 14 patients however) then it will show that CD22 plays a significant role in autoimmune disease, at least in these two indications and probably more.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News